文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

靶向去泛素化酶治疗恶性肿瘤(综述)。

Targeting the deubiquitinase for malignant tumor therapy (Review).

机构信息

Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China.

出版信息

Oncol Rep. 2023 Oct;50(4). doi: 10.3892/or.2023.8613. Epub 2023 Aug 18.


DOI:10.3892/or.2023.8613
PMID:37594087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10463009/
Abstract

The ubiquitin‑proteasome system is a major degradation pathway for >80% of proteins . Deubiquitylases, which remove ubiquitinated tags to stabilize substrate proteins, are important components involved in regulating the degradation of ubiquitinated proteins. In addition, they serve multiple roles in tumor development by participating in physiological processes such as protein metabolism, cell cycle regulation, DNA damage repair and gene transcription. The present review systematically summarized the role of ubiquitin‑specific protease 2 (USP2) in malignant tumors and the specific molecular mechanisms underlying the involvement of in tumor‑associated pathways. reverses ubiquitin‑mediated degradation of proteins and is involved in aberrant proliferation, migration, invasion, apoptosis and drug resistance of tumors. Additionally, the present review summarized studies reporting on the use of as a therapeutic target for malignancies such as breast, liver, ovarian, colorectal, bladder and prostate cancers and glioblastoma and highlights the current status of pharmacological research on . The clinical significance of as a therapeutic target for malignant tumors warrants further investigation.

摘要

泛素-蛋白酶体系统是 >80%的蛋白质的主要降解途径。去泛素化酶通过去除泛素化标签来稳定底物蛋白,是参与调节泛素化蛋白降解的重要组成部分。此外,它们通过参与蛋白质代谢、细胞周期调控、DNA 损伤修复和基因转录等生理过程,在肿瘤发生发展中发挥多种作用。本综述系统总结了泛素特异性蛋白酶 2 (USP2) 在恶性肿瘤中的作用及其在肿瘤相关途径中参与的具体分子机制。USP2 逆转了泛素介导的蛋白质降解,并参与肿瘤的异常增殖、迁移、侵袭、凋亡和耐药。此外,本综述还总结了将 USP2 作为乳腺癌、肝癌、卵巢癌、结直肠癌、膀胱癌、前列腺癌和胶质母细胞瘤等恶性肿瘤的治疗靶点的研究报告,并强调了 USP2 药理学研究的现状。USP2 作为恶性肿瘤治疗靶点的临床意义值得进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce84/10463009/ebb9eb3dee61/or-50-04-08613-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce84/10463009/afd897e992f0/or-50-04-08613-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce84/10463009/1140afe992ba/or-50-04-08613-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce84/10463009/8f6aa0532532/or-50-04-08613-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce84/10463009/ebb9eb3dee61/or-50-04-08613-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce84/10463009/afd897e992f0/or-50-04-08613-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce84/10463009/1140afe992ba/or-50-04-08613-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce84/10463009/8f6aa0532532/or-50-04-08613-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce84/10463009/ebb9eb3dee61/or-50-04-08613-g03.jpg

相似文献

[1]
Targeting the deubiquitinase for malignant tumor therapy (Review).

Oncol Rep. 2023-10

[2]
USP2-Related Cellular Signaling and Consequent Pathophysiological Outcomes.

Int J Mol Sci. 2021-1-26

[3]
Ribonucleotide reductase holoenzyme inhibitor COH29 interacts with deubiquitinase ubiquitin-specific protease 2 and downregulates its substrate protein cyclin D1.

FASEB J. 2022-5

[4]
Loss of deubiquitylase USP2 triggers development of glioblastoma via TGF-β signaling.

Oncogene. 2022-4

[5]
Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.

J Biol Chem. 2016-11-18

[6]
The Molecular Mechanisms of Regulation on USP2's Alternative Splicing and the Significance of Its Products.

Int J Biol Sci. 2017-11-2

[7]
Yeast Two-Hybrid Analysis for Ubiquitin Variant Inhibitors of Human Deubiquitinases.

J Mol Biol. 2019-2-11

[8]
Deubiquitinase USP2 stabilizes the MRE11-RAD50-NBS1 complex at DNA double-strand break sites by counteracting the ubiquitination of NBS1.

J Biol Chem. 2023-1

[9]
Therapeutic targeting of the USP2-E2F4 axis inhibits autophagic machinery essential for zinc homeostasis in cancer progression.

Autophagy. 2022-11

[10]
Inhibition of USP2 Enhances TRAIL-Mediated Cancer Cell Death through Downregulation of Survivin.

Int J Mol Sci. 2023-8-15

引用本文的文献

[1]
USP41 plays carcinogenic roles in human cutaneous melanoma through PI3K/Akt signaling pathway.

Arch Dermatol Res. 2025-5-20

[2]
Ubiquitin proteasome system (UPS): a crucial determinant of the epigenetic landscape in cancer.

Epigenomics. 2025-6

[3]
Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects.

Biomolecules. 2025-2-7

[4]
VCP enhances autophagy-related osteosarcoma progression by recruiting USP2 to inhibit ubiquitination and degradation of FASN.

Cell Death Dis. 2024-11-3

本文引用的文献

[1]
YWK-II/APLP2 inhibits TGF-β signaling by interfering with the TGFBR2-Hsp90 interaction.

Biochim Biophys Acta Mol Cell Res. 2023-10

[2]
Genome-wide CRISPR screens define determinants of epithelial-mesenchymal transition mediated immune evasion by pancreatic cancer cells.

Sci Adv. 2023-7-14

[3]
Cell Cycle-Related lncRNAs as Innovative Targets to Advance Cancer Management.

Cancer Manag Res. 2023-7-3

[4]
Oncogene-like addiction to aneuploidy in human cancers.

Science. 2023-8-25

[5]
Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy.

Nat Commun. 2023-4-6

[6]
USP2 Inhibits Lung Cancer Pathogenesis by Reducing ARID2 Protein Degradation via Ubiquitination.

Biomed Res Int. 2022

[7]
PTEN Deficiency Facilitates Exosome Secretion and Metastasis in Cholangiocarcinoma by Impairing TFEB-mediated Lysosome Biogenesis.

Gastroenterology. 2023-3

[8]
UBP12/UBP13-mediated deubiquitination of salicylic acid receptor NPR3 suppresses plant immunity.

Mol Plant. 2023-1-2

[9]
Sustained co-delivery of 5-fluorouracil and cis-platinum via biodegradable thermo-sensitive hydrogel for intraoperative synergistic combination chemotherapy of gastric cancer.

Bioact Mater. 2022-11-8

[10]
ARID2 mitigates hepatic steatosis via promoting the ubiquitination of JAK2.

Cell Death Differ. 2023-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索